Stay updated on Mirvetuximab Combo in FRα+ Ovarian Cancer Clinical Trial
Sign up to get notified when there's something new on the Mirvetuximab Combo in FRα+ Ovarian Cancer Clinical Trial page.

Latest updates to the Mirvetuximab Combo in FRα+ Ovarian Cancer Clinical Trial page
- Check5 days agoChange DetectedThe page now shows an updated Revision tag (v3.6.4), replacing the prior revision (v3.6.3) in the page metadata.SummaryDifference0.0%

- Check12 days agoNo Change Detected
- Check19 days agoNo Change Detected
- Check26 days agoChange DetectedA new revision tag 'Revision: v3.6.3' was added, replacing the previous 'Revision: v3.6.0' tag to indicate an updated patch version on the page.SummaryDifference0.0%

- Check41 days agoChange DetectedNew guidance sections were added to help readers read the study record and understand how to join. The recruitment status was updated to No longer looking for participants, indicating enrollment has closed.SummaryDifference0.3%

- Check48 days agoChange DetectedRevision tag for the study documents updated from v3.5.4 to v3.5.5. This reflects an updated version of the documents referenced on the page.SummaryDifference0.0%

- Check62 days agoChange DetectedPublication details for a PubMed-listed article related to the study were added under Publications, including authors, title, journal, year, and DOI. A note explains that some entries are auto-filled from PubMed and may not be exclusively about the study.SummaryDifference0.2%

- Check69 days agoChange DetectedA new Revision: v3.5.4 appears on the page, replacing the previous Revision: v3.5.3. This update reflects a minor version change in the page's metadata rather than substantive content changes.SummaryDifference0.0%

Stay in the know with updates to Mirvetuximab Combo in FRα+ Ovarian Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Mirvetuximab Combo in FRα+ Ovarian Cancer Clinical Trial page.